title: Too-low iron doses and too many dropouts in negative iron trial?
authors.forename: Matti
authors.initials: M
authors.lastname: Aapro
authors.forename: Yves
authors.initials: Y
authors.lastname: Beguin
authors.forename: Gunnar
authors.initials: G
authors.lastname: Birgegård
authors.forename: Pere
authors.initials: P
authors.lastname: Gascón
authors.forename: Michael
authors.initials: M
authors.lastname: Hedenus
authors.forename: Anders
authors.initials: A
authors.lastname: Osterborg
mesh_terms: D000740:Anemia / Q000188:drug therapy*; D000970:Antineoplastic Agents / Q000009:adverse effects; D005290:Ferric Compounds / Q000009:adverse effects; D006801:Humans; D007501:Iron / Q000008:administration & dosage* / Q000009:adverse effects; D010352:Patient Dropouts; D016032:Randomized Controlled Trials as Topic; D014168:Transferrin / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; D005290:Ferric Compounds; D014168:Transferrin; D007501:Iron; C035552:ferric gluconate